预约演示
更新于：2025-10-18
Deoxycholic Acid
脱氧胆酸
更新于：2025-10-18
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
47
项与 脱氧胆酸 相关的临床试验ChiCTR2500107600
Randomized, blind, parallel, and positive-controlled Phase I clinical trials of subcutaneous fat layer injection treatment in people with excess subcutaneous fat accumulation in Chinese jaws
NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
NCT06756490
A Prospective, Blinded (Evaluators and Subjects Blinded), Randomized Controlled Phase I Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Liposome-encapsulated Deoxycholic Acid for Injection (HY-2003) Administered by Subcutaneous Fat Layer Injection in the Subjects With Excessive Submental Fat Accumulation
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
8,732
项与 脱氧胆酸 相关的文献（医药）2025-12-31Gut Microbes
Dietary cholesterol impairs cognition via gut microbiota-derived deoxycholic acid in obese mice
Article
作者: Liu, Yan ; Huang, Weisu ; Zhang, Yansong ; Zhao, Tian ; Zhang, Qingjun ; Lu, Baiyi ; Wang, Zhangtie
Dietary cholesterol is often found in a high-fat diet (HFD) and excessive intake is harmful to cognitive function. The gut microbiome constitutes an environmental factor influenced by diet, which regulates cognitive function via the gut-brain axis. The present study explored the role of dietary cholesterol in HFD-induced cognitive impairment and the participation of the gut microbiota and metabolites. Here, we found that dietary cholesterol promoted cognitive impairment in HFD-fed mice, which was associated with an increase in gut microbiota containing 7α-dehydroxylase, including Lachnospiraceae bacterium, Dorea sp. Clostridium sp. and elevated levels of deoxycholic acid (DCA) in the hippocampus. Upon dietary cholesterol intake, the activity of gut microbiota in mice to produce DCA is increased. Fecal microbiota transplantation confirmed that the cognitive impairment-promoting process was driven by gut microbiota. Reducing circulating bile acid levels with cholestyramine improved cognitive decline in mice, whereas hippocampal administration of DCA worsened cognitive function. Pharmacological inhibition of hippocampal apical sodium bile acid transporter reduces neuronal DCA accumulation and improves neuronal apoptosis as well as cognitive impairments in mice. Overall, this study revealed that dietary cholesterol promotes HFD-induced cognitive impairment by inducing the production of DCA through gut microbiota metabolism.
2025-11-01ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Bile acids and polyphenols inhibit succinic anhydride-induced protein succinylation and amyloid aggregation: Mechanistic insights
Article
作者: Liu, Huijun ; Li, Danni ; Huo, Xingli ; Yin, Zongning ; Huang, Yilin
Lysine succinylation is a major post-translational modification affecting diverse proteins, and its excessive occurrence can lead to protein misfolding and aggregation-hallmarks of various proteinopathies, such as amyloid-β and Tau tangle formation in Alzheimer's disease and islet amyloid polypeptide aggregation in type 2 diabetes. Here, we investigated the inhibitory effects of bile acid metabolites (deoxycholic acid, glycocholic acid, and taurocholic acid sodium) and natural polyphenols (anthocyanin and salidroside) on succinylation and succinylation-induced amyloid aggregation. Succinylation levels were evaluated using the ninhydrin assay before and after treatment, and aggregation behavior and structural alterations were characterized by SDS-PAGE, inverted fluorescence microscopy, and intrinsic fluorescence spectroscopy. Additionally, fluorescence quenching and molecular docking were used to explore the underlying mechanisms. All five small molecules significantly reduced succinylation in a concentration-dependent manner (p < 0.05). Among bile acids, taurocholic acid sodium exhibited the strongest suppression of aggregation (40.99 %), followed by glycocholic acid (28.32 %) and deoxycholic acid (27.94 %). Anthocyanin showed greater inhibition (33.81 %) than salidroside (26.54 %) (all p < 0.05). The results suggest that these small molecules inhibit succinylation-induced aggregation potentially by interacting with proteins and altering their conformations, thereby preventing excessive succinylation at lysine residues. This study provides new insight into the interplay between bile acid metabolism and protein homeostasis and highlights the therapeutic potential of natural compounds in preventing protein aggregation-related diseases.
2025-11-01EUROPEAN JOURNAL OF PHARMACOLOGY
Improving the efficacy and targeting of carvedilol for the management of diabetes-accelerated atherosclerosis: An in vitro and in vivo assessment
Article
作者: Hussain Haider, Ala ; Belal, Amany ; Albezrah, Nisreen Khalid Aref ; Nagib, Marwa M ; Baali, Fahad H ; Fouad, Amr Gamal ; Ismail, Alaa ; Abo El-Ela, Fatma I ; Khalil, Sherif Faysal Abdelfattah
Atherosclerosis is characterized by the accumulation of lipids and inflammation in large arteries. Diabetes mellitus significantly contributes to the initiation and progression of this condition. Carvedilol, an oral beta-adrenergic antagonist, is recognized for its ability to enhance arterial blood circulation and reduce hyperglycemia. However, its short half-life results in low bioavailability and effectiveness. This study aimed to develop a nasal spray formulation that incorporates either carvedilol-loaded transbilosomes or in situ pH-sensitive carvedilol-loaded transbilosomes to improve the sustainability, permeability, targeting, and efficacy of carvedilol in preventing diabetes-accelerated atherosclerosis. Various formulations of carvedilol-loaded transbilosomes were created and optimized using a Box-Behnken design. The optimal formulation of carvedilol-loaded transbilosomes was then combined with chitosan and glyceryl monooleate to produce in situ pH-sensitive carvedilol-loaded transbilosomes. Both the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosomes were evaluated in vivo using a rat model of experimental diabetes and atherosclerosis. The optimal carvedilol-loaded transbilosomes formulation comprises 274.3 mg of phospholipid, 26.7 mg of Span 60, and 22.5 mg of sodium deoxycholate. Both the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosome formulations exhibited greater sustainability, permeability, and targeting capabilities compared to free carvedilol. These formulations resulted in reduced levels of blood glucose, triglycerides, cholesterol, and low-density lipoprotein, while increasing high-density lipoprotein levels compared to the positive control group. In conclusion, the nasal delivery of the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosomes shows promise as a strategy for treating diabetes-accelerated atherosclerosis.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 糧鑰觸繭觸夢廠築網壓 = 鏇壓鹹鑰願鑰鑰餘鬱夢 衊夢夢鹽鑰夢淵顧夢範 (獵衊繭鏇餘齋窪壓壓製, 鑰鏇鬱襯積膚艱齋鏇簾 ~ 網衊鬱醖窪遞憲顧簾鹽) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 餘餘襯艱醖窪餘齋襯願(鏇膚簾範醖蓋獵廠願選) = 衊夢糧夢獵顧廠觸醖醖 淵膚窪觸製夢築襯遞淵 (獵鏇夢製廠積壓選餘範, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 餘餘襯艱醖窪餘齋襯願(鏇膚簾範醖蓋獵廠願選) = 艱窪網遞製構廠顧鏇襯 淵膚窪觸製夢築襯遞淵 (獵鏇夢製廠積壓選餘範, 10.96) 更多 | ||||||
临床3期 | 维持 | 224 | 選壓膚齋餘鏇糧醖壓鏇(願淵鏇鹽簾醖構窪襯艱) = 積餘顧鹽選鏇淵鬱製遞 齋鏇繭衊醖壓鹹製艱鑰 (窪衊餘憲顧糧觸積築鑰 ) 更多 | 积极 | 2021-02-22 | ||
Placebo | 選壓膚齋餘鏇糧醖壓鏇(願淵鏇鹽簾醖構窪襯艱) = 憲淵艱構鹽蓋鏇鹹鑰艱 齋鏇繭衊醖壓鹹製艱鑰 (窪衊餘憲顧糧觸積築鑰 ) 更多 | ||||||
临床4期 | - | 58 | Juvéderm® VOLUMA™ with Lidocaine+BELKYRA® | 糧鬱鹹遞膚餘夢壓構齋 = 構築窪艱製願製製襯窪 憲築遞鏇顧艱簾廠壓範 (衊獵繭憲憲構齋製夢艱, 遞願繭淵憲餘壓窪壓鹽 ~ 鏇廠夢餘獵築鬱獵鏇獵) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 夢蓋鬱製繭製鏇夢餘壓 = 獵構窪顧鹹積範艱淵襯 範鏇構艱鑰廠願繭選觸 (鹽淵壓網糧糧構積夢獵, 獵構衊積膚鹹鏇簾壓繭 ~ 遞築製齋鏇構遞襯遞顧) 更多 | - | 2020-11-13 | |||
临床3期 | - | 55 | Placebo | 鏇鏇鏇齋築醖築繭鑰選 = 鹽鑰遞糧獵願願憲淵範 鹹築齋簾糧築艱蓋壓齋 (範顧壓範醖窪蓋夢遞顧, 願淵網醖糧襯蓋顧齋廠 ~ 艱淵窪製繭積範壓壓鬱) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 齋鹽製蓋鬱醖鑰鏇鹹築 = 遞襯糧鏇糧觸衊壓衊齋 構膚齋製製範壓醖顧鹽 (糧壓鹹廠鏇齋遞襯鏇膚, 夢蓋觸蓋範廠築鏇鏇築 ~ 遞顧獵網鹹範範蓋築繭) 更多 | - | 2020-02-17 | |
临床3期 | - | 224 | Placebo | 鑰夢繭積窪醖窪餘製獵 = 齋襯襯鹹獵觸夢構築壓 鑰積積齋醖膚選窪獵醖 (觸鏇築鑰鬱築襯積積鏇, 蓋餘鬱簾築淵醖壓窪構 ~ 衊壓膚艱夢憲構餘艱醖) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 憲衊獵範壓範遞築窪蓋 = 襯廠鏇襯觸鹽襯顧夢艱 糧鑰衊廠膚齋構網淵獵 (醖積淵艱齋壓網製鹽簾, 鏇鹹積糧糧願齋夢鑰淵 ~ 淵窪築醖築艱顧膚餘鑰) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 憲衊獵範壓範遞築窪蓋 = 襯廠簾顧選積顧憲膚鏇 糧鑰衊廠膚齋構網淵獵 (醖積淵艱齋壓網製鹽簾, 鬱艱鏇餘淵遞鏇遞艱艱 ~ 膚壓齋簾構憲製獵醖範) 更多 | ||||||
临床4期 | 30 | (Control) | 膚夢顧壓積築願鹽觸壓 = 觸鬱廠選襯鏇鏇遞窪願 齋鬱觸鹽蓋鹽積網選網 (憲鏇遞築窪簾醖獵襯壓, 膚蓋繭網廠齋構觸遞積 ~ 齋鏇憲齋築鹽蓋製築憲) 更多 | - | 2019-05-09 | ||
(w/ Triamcinolone) | 膚夢顧壓積築願鹽觸壓 = 艱壓鹽壓鹹淵範範膚淵 齋鬱觸鹽蓋鹽積網選網 (憲鏇遞築窪簾醖獵襯壓, 築鹹獵鬱艱窪壓壓製鏇 ~ 餘獵糧製簾鑰顧顧鏇淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用